1.Clinical characteristics of digestive system cancers metastatic to the heart.
Jia Lin TANG ; Bo ZHANG ; Xing Yuan WANG ; Yan SONG ; Jian Ping XU ; Tao QU ; Yihebali CHI ; Jing HUANG
Chinese Journal of Oncology 2022;44(11):1229-1232
Objective: To investigate the clinical features of patients with cardiac metastases from digestive system tumors. Methods: This retrospective study collected and analyzed the medical records of patients with cardiac metastases from digestive system tumors who received treatments in the Cancer Hospital, Chinese Academy of Medical Sciences between January 1999 and January 2021. Kaplan-Meier method was used for survival analysis. Results: A total of 19 patients were identified. The primary tumors were esophageal squamous cell carcinoma (n=7), gastric or gastroesophageal junction adenocarcinoma (n=6), hepatobiliary cancers (n=3) and colorectal cancers (n=3). 16 patients had pericardial metastases, 2 patients had right atrium metastases, and 1 patient had left ventricle metastasis. The most common symptom was dyspnea, which was present in 8 cases. 7 patients received locoregional treatment, while 11 patients underwent systemic therapies. The median overall survival from diagnosis of primary cancer was 31.4 months, and the median overall survival time from diagnosis of cardiac metastasis was 4.7 months. Conclusion: Cardiac metastasis from digestive system tumors is associated with low incidence and a poor prognosis. Systemic treatment remains the cornerstone of management, while novel anti-tumor drugs may improve therapeutic efficacy.
Humans
;
Esophageal Neoplasms/pathology*
;
Retrospective Studies
;
Prognosis
;
Esophageal Squamous Cell Carcinoma
;
Digestive System Neoplasms/drug therapy*
;
Gastrointestinal Neoplasms
2.New concepts in surgical treatment of rectal cancer.
Chinese Journal of Oncology 2012;34(3):161-164
3.Progress in research on applying Sijunzi Decoction in treating digestive malignant tumor.
Chinese journal of integrative medicine 2007;13(2):156-159
Patients with digestive malignant tumor always have their immune function, especially the cellular immunity, suppressed to a certain extent. Traditional Chinese medicine (TCM) holds that Pi-Wei is the essence of postnatal life, and the genesis and development of digestive tumor are chiefly due to the insufficiency of vital-qi, which makes the body open to the invasion of evil pathogens. Starting from regulating the immune function of organisms, researchers recently obtained some therapeutic effects by applying the Chinese recipe, Sijunzi Decoction, in the treatment of digestive malignant tumors. In this paper, the related studies on the concerned basic theory and clinical application were reviewed.
Apoptosis
;
drug effects
;
Digestive System Neoplasms
;
drug therapy
;
immunology
;
pathology
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
Neoplasm Metastasis
4.A Case of Synchronous Esophagus and Stomach Cancer Successfully Treated by Combined Chemotherapy.
Ji Sun HAN ; Seok Reyol CHOI ; Jin Seok JANG ; Myung Hwan ROH ; Dae Cheol KIM ; Seung Hee RYU ; Su Mi WOO ; Chien Ter HSING
The Korean Journal of Gastroenterology 2012;60(2):113-118
Although cases of simultaneous esophagus and stomach cancer have been reported sporadically, there are rare reports of successful treatment using chemotherapy. We report a case of synchronous esophageal and gastric cancer successfully treated using docetaxel and cis-diammineedichloro-platinum (CDDP) combination chemotherapy instead of surgery. A 82-years-old man with anorexia and progressive weight loss was diagnosed with synchronous esophageal and gastric cancer by endoscopy. Both cancers were diagnosed as resectable by the preoperative clinical staging. However, surgery was contraindicated because of severe lung dysfunction. Moreover, he actively refused radiotherapy and endoscopic management. Therefore, the patient was given combined chemotherapy with docetaxel (65 mg/m2) and CDDP (60 mg/m2). The esophageal and gastric lesion completely disappeared on endoscopy, and there were no residual tumor cells on endoscopic biopsy after three cycles of chemotherapy. Metastatic lymph nodes also completely disappeared on the CT scan. The patient received a total of ten cycles of chemotherapy, without severe adverse effects. The patient remained asymptomatic for 18 months after discontinuation of the chemotherapy, without evidence of local recurrence or distant metastasis. Surgery or endoscopic treatment of both esophageal and gastric cancers is desirable, but, if medically inoperable, chemotherapy can be alternative treatment option.
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Cisplatin/therapeutic use
;
Drug Therapy, Combination
;
Endoscopy, Digestive System
;
Esophageal Neoplasms/complications/*drug therapy/pathology
;
Humans
;
Male
;
Positron-Emission Tomography
;
Stomach Neoplasms/complications/*drug therapy/pathology
;
Taxoids/therapeutic use
;
Tomography, X-Ray Computed
5.Gastric Burkitt Lymphoma in a Six Year-old Boy Presenting with Upper Gastrointestinal Bleeding
Min Sun KIM ; Hyunwoo SUNG ; Seung Beom HAN ; Jae Wook LEE ; Nack Gyun CHUNG ; Bin CHO ; Jin Han KANG ; Hack Ki KIM
Clinical Pediatric Hematology-Oncology 2013;20(2):116-120
Childhood Burkitt lymphoma is most often diagnosed in the abdomen, with the majority of intra-abdominal cases arising from the small or large intestines. Involvement of the gastric mucosa is rare. Here, we present a six-year-old boy who was found to have gastric Burkitt lymphoma through biopsy obtained by esophagogastroduodenoscopy. The child was treated with six cycles of chemotherapy without surgery, and he remains free of disease fourteen months since initial diagnosis. Early definitive diagnosis through endoscopic biopsy and appropriate treatment are necessary for rare instances where children present with upper gastrointestinal tract tumors.
Abdomen
;
Biopsy
;
Burkitt Lymphoma
;
Child
;
Diagnosis
;
Drug Therapy
;
Endoscopy
;
Endoscopy, Digestive System
;
Gastric Mucosa
;
Hematemesis
;
Hemorrhage
;
Humans
;
Intestines
;
Lymphoma, Non-Hodgkin
;
Male
;
Stomach Neoplasms
;
Upper Gastrointestinal Tract
6.Experimental study on anti-neoplastic activity of epigallocatechin-3-gallate to digestive tract carcinomas.
Zhi-hua RAN ; Jian ZOU ; Shu-dong XIAO
Chinese Medical Journal 2005;118(16):1330-1337
BACKGROUNDEpigallocatechin-3-gallate (EGCG) has been demonstrated to have anti-neoplastic activity, but the effective concentration of EGCG and its possible mechanisms are uncertain. The study on the killing effects of EGCG on different digestive tract cancer cell lines can find target sites of its anti-neoplastic effect and provide a theoretical basis for its clinical application in the treatment of cancers.
METHODSMethyl thiazolyl tetrazolium (MTT) analysis was made to detect the differential sensitivities of eight digestive tract cancer cell lines to EGCG. The effect of EGCG on cell cycle distribution of sensitive cancer cell line was measured by flow cytometry. By polymerase chain reaction (PCR)-enzyme linked immunosorbent assay (ELISA) protocol, the influence of EGCG on telomerase activity of sensitive cancer cell line was also investigated. RT-PCR method was employed to detect the influence of EGCG on the expressions of hTERT, c-myc, p53 and mad1 genes in sensitive cancer cell line.
RESULTSEGCG exhibited dose-dependent killing effects on all eight digestive tract cancer cell lines. The 50% inhibitory concentration (IC50) of SW1116, MKN45, BGC823, SGC7901, AGS, MKN28, HGC27 and LoVo cells were 51.7 micromol/L, 55.9 micromol/L, 68.5 micromol/L, 79.1 micromol/L, 83.8 micromol/L, 119.8 micromol/L, 183.2 micromol/L and 194.6 micromol/L, respectively. There were no apparent changes in cell cycle distribution of sensitive cancer cell line MKN45 48 hours after incubating with three different concentrations of EGCG compared with the controls. It was found that EGCG could suppress the telomerase activity of MKN45 cells, and the effects were dose- and time-dependent. After EGCG administration, the expression of hTERT and c-myc genes in MKN45 cells was decreased, that of the mad1 gene increased, and that of the p53 gene unchanged.
CONCLUSIONSEGCG has dose-dependent killing effects on different digestive tract cancer cell lines. Administration of EGCG has no obvious effect on cell cycle distribution of sensitive cancer cell line MKN45. The anti-neoplastic activity of EGCG might be due to the inhibition of telomerase activity by means of its influence on hTERT and the up-stream regulation genes.
Antineoplastic Agents ; pharmacology ; Catechin ; analogs & derivatives ; pharmacology ; Cell Cycle ; drug effects ; Cell Line, Tumor ; DNA-Binding Proteins ; genetics ; Digestive System Neoplasms ; drug therapy ; metabolism ; pathology ; Dose-Response Relationship, Drug ; Genes, myc ; Genes, p53 ; Humans ; Telomerase ; genetics ; metabolism
7.Improved Survival of a Patient with Gastric and Other Multiple Metastases from Ovarian Cancer by Multimodal Treatment: A Case Report.
Seonmi HWANGBO ; Oh Kyoung KWON ; Ho Young CHUNG ; Wansik YU
Journal of Gastric Cancer 2015;15(3):218-221
Gastric metastasis from ovarian carcinoma is extremely rare and the prognosis for patients is poor. We report a case of multimodal treatment improving the survival time of a patient with gastric metastasis from ovarian cancer. A 73-year-old woman with known serous ovarian cancer was admitted to the hospital due to epigastric pain and dyspepsia. On esophagogastroduodenoscopy, a protruding mass was noted at the gastric antrum. She underwent distal gastrectomy with Billroth I anastomosis and lymph node dissection, including the para-aortic lymph nodes. The final pathology revealed gastric metastasis from ovarian serous adenocarcinoma. In this case, after cytoreductive surgery, chemotherapy was performed each time a recurrence was diagnosed, and remission was accomplished. She survived for 108 months after the first diagnosis of the metastatic tumor in the stomach. Multimodal treatment of metastatic lesions since the first diagnosis allowed the patient to survive longer than those in previous reports.
Adenocarcinoma
;
Aged
;
Combined Modality Therapy*
;
Diagnosis
;
Drug Therapy
;
Dyspepsia
;
Endoscopy, Digestive System
;
Female
;
Gastrectomy
;
Gastroenterostomy
;
Humans
;
Lymph Node Excision
;
Lymph Nodes
;
Neoplasm Metastasis*
;
Ovarian Neoplasms*
;
Pathology
;
Prognosis
;
Pyloric Antrum
;
Recurrence
;
Stomach
8.Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy.
Yanwu SUN ; Pan CHI ; Huiming LIN ; Xingrong LU ; Ying HUANG ; Zongbing XU ; Shenghui HUANG ; Daoxiong YE ; Xiaojie WANG
Chinese Journal of Gastrointestinal Surgery 2016;19(4):436-441
OBJECTIVETo clarify the natural course and explore impact factors of distant metastasis in rectal cancer patients who received total mesorectal excision(TME) following neoadjuvant chemoradiotherapy (CRT).
METHODSBetween Januray 2008 and December 2013, 317 patients with locally advanced rectal cancer who underwent radical surgical resection following neoadjuvant CRT (pre- and postoperative simple fluorouracil or fluorouracil combined with oxaliplatin plus preoperative three dimensional conformal radiotherapy) at Department of Colorectal Surgery in Fujian Medical University Union Hospital were included. Univariate analysis and Cox regression were performed to evaluate the clinicopathological parameters that may be associated with distant metastasis.
RESULTSDuring a median follow-up of 39 months(range 15 - 89 months), 72 patients(22.7%) had disease recurrence, including local recurrence in 8 patients, and distant metastasis in 67 patients (among whom 3 patients had both). Distant metastasis occurred in 86.5%(58/67) patients during the first three years after surgery. The 3-year cumulative distant metastatic rate in all the patients was 22.4%. The 5-year overall survival rate in distant metastatic patient was significantly lower than that of non-distant metastatic patients following neoadjuvant CRT (36.2% vs. 81.2%, P=0.000). Univariate analysis showed that ypT stage (χ(2)=13.304, P=0.010), ypN stage(χ(2)=23.416, P=0.000), ypTNM stage (χ(2)=31.765, P=0.000) and RCRG(χ(2)=16.246, P=0.000) were associated with distant metastasis. Cox regression revealed that ypTNM stage(HR=1.959, 95% CI:1.171 ~ 3.277, P=0.010) was the only independent risk factor of distant metastasis.
CONCLUSIONSDistant metastasis is the early event during the progression in rectal cancer. ypTNM stage is the only independent risk factor of distant metastasis in locally advanced rectal cancer patients who undergo TME following neoadjuvant CRT.
Chemoradiotherapy ; Digestive System Surgical Procedures ; Fluorouracil ; therapeutic use ; Humans ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Organoplatinum Compounds ; therapeutic use ; Rectal Neoplasms ; drug therapy ; pathology ; surgery ; Risk Factors ; Survival Rate
9.Effectiveness of Recombinant Human Growth Hormone for Pharyngocutaneous Fistula Closure.
Nurten KUCUK ; Murat SARI ; Ahmet MIDI ; Ali Cemal YUMUSAKHUYLU ; Ozan FINDIK ; Adem BINNETOGLU
Clinical and Experimental Otorhinolaryngology 2015;8(4):390-395
OBJECTIVES: In laryngeal cancer, which comprises 25% of head and neck cancer, chemotherapy has come into prominence with the increase in organ-protective treatments. With such treatment, salvage surgery has increased following recurrence; the incidence of pharyngocutaneous fistula has also increased in both respiratory and digestive system surgery. We investigated the effects of recombinant human growth hormone on pharyngocutaneous fistula closure in Sprague-Dawley rats, based on an increase in amino acid uptake and protein synthesis for wound healing, an increase in mitogenesis, and enhancement of collagen formation by recombinant human growth hormone. METHODS: This study was experimental animal study. Forty Sprague-Dawley rats were separated into two groups, and pharyngoesophagotomy was performed. The pharyngoesophagotomy was sutured with vicryl in both groups. Rats in group 1 (control group) received no treatment, while those in group 2 were administered a subcutaneous injection of recombinant human growth hormone daily. On day 14, the pharynx, larynx, and upper oesophagus were excised and examined microscopically. RESULTS: Pharyngocutaneous fistula exhibited better closure macroscopically in the recombinant human growth hormone group. There was a significant difference in collagen formation and epithelisation in the recombinant human growth hormone group compared to the control group. CONCLUSION: This study is believed to be the first in which the effect of recombinant human growth hormone on pharyngocutaneous fistula closure was evaluated, and the findings suggest the potential of use of growth hormone for treatment of pharyngocutaneous fistula.
Animals
;
Collagen
;
Digestive System
;
Drug Therapy
;
Fistula*
;
Growth Hormone
;
Head and Neck Neoplasms
;
Human Growth Hormone*
;
Humans*
;
Incidence
;
Injections, Subcutaneous
;
Laryngeal Neoplasms
;
Larynx
;
Pharynx
;
Polyglactin 910
;
Rats
;
Rats, Sprague-Dawley
;
Recurrence
;
Wound Healing
10.Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Raffaella MARCHESELLI ; Luigi MARCHESELLI ; Laura CORTESI ; Alessia BARI ; Claudia CIRILLI ; Samantha POZZI ; Paola FERRI ; Martina NAPOLITANO ; Massimo FEDERICO ; Stefano SACCHI
Journal of Breast Cancer 2015;18(4):378-385
PURPOSE: Evolving therapies have improved the prognoses of patients with breast cancer; and currently, the number of long-term survivors is continuously increasing. However, these patients are at increased risk of developing a second cancer. Thus, late side effects are becoming an important issue. In this study, we aimed to investigate whether patient and tumor characteristics, and treatment type correlate with secondary tumor risk. METHODS: This case-control study included 305 patients with a diagnosed second malignancy after almost 6 months after the diagnosis of primary breast cancer and 1,525 controls (ratio 1:5 of cases to controls) from a population-based cohort of 6,325 women. The control patients were randomly selected from the cohort and matched to the cases according to age at diagnosis, calendar period of diagnosis, disease stage, and time of follow-up. RESULTS: BRCA1 or BRCA2 mutation, human epidermal growth factor receptor 2 (HER2)+ status, chemotherapy, and radiotherapy were related to increased risk of developing a second cancer, whereas hormonotherapy showed a protective effect. Chemotherapy, radiotherapy, and estrogenic receptor level <10% increased the risk of controlateral breast cancer. HER2+ status increased the risk of digestive system and thyroid tumors, while BRCA1 or BRCA2 mutation increased the risk of cancer in the genital system. CONCLUSION: Breast cancer survivors are exposed to an excess of risk of developing a second primary cancer. The development of excess of malignancies may be related either to patient and tumor characteristics, such as BRCA1 or BRCA2 mutation and HER2+ status, or to treatments factors.
Breast Neoplasms*
;
Breast*
;
Case-Control Studies*
;
Cohort Studies
;
Diagnosis
;
Digestive System
;
Drug Therapy
;
Estrogens
;
Female
;
Follow-Up Studies
;
Humans
;
Neoplasms, Second Primary
;
Prognosis
;
Radiotherapy
;
Receptor, Epidermal Growth Factor
;
Survivors*
;
Thyroid Gland